Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Vital KSK Holdings, Inc. ( (JP:3151) ) is now available.
Vital KSK Holdings, Inc. announced that its subsidiary, VITAL-NET, Inc., has entered into an exclusive license agreement with Shield Therapeutics plc for the development and commercialization of ACCRUFeR®, an iron deficiency treatment, in Japan. This strategic move aims to expand Vital KSK’s pharmaceutical offerings in Japan, with plans to build a comprehensive distribution and sales network. The agreement involves upfront and milestone payments, as well as royalties, and is expected to enhance the company’s market position and product value chain.
More about Vital KSK Holdings, Inc.
Vital KSK Holdings, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of medical treatments. Its subsidiary, VITAL-NET, Inc., is involved in the Japanese market, particularly in the distribution and sales of pharmaceutical products.
YTD Price Performance: 7.26%
Average Trading Volume: 62,045
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen59.26B
See more data about 3151 stock on TipRanks’ Stock Analysis page.